New Immune-Calming therapy could slow progressive MS

NCT ID NCT07020715

Not yet recruiting Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase IIa trial tests a personalized cell therapy for people with progressive multiple sclerosis (MS). The treatment uses the patient's own immune cells, turned into 'tolerogenic dendritic cells' that are designed to calm the immune system and stop it from attacking the nerves. Fourteen participants will receive the therapy and be monitored for safety and disability progression over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tolerogenic dendritic cells (tolDC) made from the patient's own blood cells
What this could lead to: If successful, this could lead to a treatment that slows or stops disability progression in people with progressive multiple sclerosis.
What could go wrong: This is a very early, small trial with only 14 participants, so results may not apply to everyone. The therapy is complex and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Germans Trias i Pujol Hospital (HUGTiP)

Badalona, 08916, Spain
Universitair Ziekenhuis Antwerpen (UZA)

Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.